Literature DB >> 23510994

1H NMR-based spectroscopy detects metabolic alterations in serum of patients with early-stage ulcerative colitis.

Ying Zhang1, Lianjie Lin, Yanbin Xu, Yan Lin, Yu Jin, Changqing Zheng.   

Abstract

Ulcerative colitis (UC) has seriously impaired the health of citizens. Accurate diagnosis of UC at an early stage is crucial to improve the efficiency of treatment and prognosis. In this study, proton nuclear magnetic resonance (1H NMR)-based metabolomic analysis was performed on serum samples collected from active UC patients (n=20) and healthy controls (n=19), respectively. The obtained spectral profiles were subjected to multivariate data analysis. Our results showed that consistent metabolic alterations were present between the two groups. Compared to healthy controls, UC patients displayed increased 3-hydroxybutyrate, β-glucose, α-glucose, and phenylalanine, but decreased lipid in serum. These findings highlight the possibilities of NMR-based metabolomics as a non-invasive diagnostic tool for UC.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23510994     DOI: 10.1016/j.bbrc.2013.03.012

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  16 in total

Review 1.  Gut microbiota-derived metabolites as key actors in inflammatory bowel disease.

Authors:  Aonghus Lavelle; Harry Sokol
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-02-19       Impact factor: 46.802

2.  Microbial Metabolomics: From Methods to Translational Applications.

Authors:  Rui Guo; Xialin Luo; Xu Xin; Lian Liu; Xijun Wang; Haitao Lu
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

3.  Serum and urine metabolomic fingerprinting in diagnostics of inflammatory bowel diseases.

Authors:  Tomasz Dawiskiba; Stanisław Deja; Agata Mulak; Adam Ząbek; Ewa Jawień; Dorota Pawełka; Mirosław Banasik; Agnieszka Mastalerz-Migas; Waldemar Balcerzak; Krzysztof Kaliszewski; Jan Skóra; Piotr Barć; Krzysztof Korta; Kornel Pormańczuk; Przemyslaw Szyber; Adam Litarski; Piotr Młynarz
Journal:  World J Gastroenterol       Date:  2014-01-07       Impact factor: 5.742

Review 4.  Metabolomics as a diagnostic tool in gastroenterology.

Authors:  Vicky De Preter; Kristin Verbeke
Journal:  World J Gastrointest Pharmacol Ther       Date:  2013-11-06

5.  Alterations in Lipid, Amino Acid, and Energy Metabolism Distinguish Crohn's Disease from Ulcerative Colitis and Control Subjects by Serum Metabolomic Profiling.

Authors:  Elizabeth A Scoville; Margaret M Allaman; Caroline T Brown; Amy K Motley; Sara N Horst; Christopher S Williams; Tatsuki Koyama; Zhiguo Zhao; Dawn W Adams; Dawn B Beaulieu; David A Schwartz; Keith T Wilson; Lori A Coburn
Journal:  Metabolomics       Date:  2017-12-29       Impact factor: 4.290

6.  Decreased Plasma Histidine Level Predicts Risk of Relapse in Patients with Ulcerative Colitis in Remission.

Authors:  Tadakazu Hisamatsu; Nobukazu Ono; Akira Imaizumi; Maiko Mori; Hiroaki Suzuki; Michihide Uo; Masaki Hashimoto; Makoto Naganuma; Katsuyoshi Matsuoka; Shinta Mizuno; Mina T Kitazume; Tomoharu Yajima; Haruhiko Ogata; Yasushi Iwao; Toshifumi Hibi; Takanori Kanai
Journal:  PLoS One       Date:  2015-10-16       Impact factor: 3.240

7.  Metabonomics of human fecal extracts characterize ulcerative colitis, Crohn's disease and healthy individuals.

Authors:  Jacob Tveiten Bjerrum; Yulan Wang; Fuhua Hao; Mehmet Coskun; Christian Ludwig; Ulrich Günther; Ole Haagen Nielsen
Journal:  Metabolomics       Date:  2014-06-01       Impact factor: 4.290

8.  Dietary and metabolomic determinants of relapse in ulcerative colitis patients: A pilot prospective cohort study.

Authors:  Ammar Hassanzadeh Keshteli; Floris F van den Brand; Karen L Madsen; Rupasri Mandal; Rosica Valcheva; Karen I Kroeker; Beomsoo Han; Rhonda C Bell; Janis Cole; Thomas Hoevers; David S Wishart; Richard N Fedorak; Levinus A Dieleman
Journal:  World J Gastroenterol       Date:  2017-06-07       Impact factor: 5.742

9.  Metabonomics uncovers a reversible proatherogenic lipid profile during infliximab therapy of inflammatory bowel disease.

Authors:  Jacob Tveiten Bjerrum; Casper Steenholdt; Mark Ainsworth; Ole Haagen Nielsen; Michelle Ac Reed; Karen Atkins; Ulrich Leonhard Günther; Fuhua Hao; Yulan Wang
Journal:  BMC Med       Date:  2017-10-16       Impact factor: 8.775

10.  Plasma-Free Amino Acid Profiles in Crohn's Disease: Relationship With the Crohn Disease Activity Index.

Authors:  Toshimi Chiba; Kazuyuki Suzuki; Takayuki Matsumoto
Journal:  Clin Med Insights Gastroenterol       Date:  2018-07-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.